- Home
- XTNT vs IKNA Comparison
XTNT vs IKNA Comparison
Compare XTNT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTNT
- IKNA
- Stock Information
- Founded
- XTNT N/A
- IKNA 2016
- Country
- XTNT United States
- IKNA United States
- Employees
- XTNT N/A
- IKNA N/A
- Industry
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- XTNT Health Care
- IKNA Health Care
- Exchange
- XTNT Nasdaq
- IKNA Nasdaq
- Market Cap
- XTNT 60.9M
- IKNA 63.7M
- IPO Year
- XTNT N/A
- IKNA 2021
- Fundamental
- Price
- XTNT $0.62
- IKNA $1.25
- Analyst Decision
- XTNT
- IKNA Strong Buy
- Analyst Count
- XTNT 0
- IKNA 1
- Target Price
- XTNT N/A
- IKNA $4.00
- AVG Volume (30 Days)
- XTNT 96.0K
- IKNA 267.0K
- Earning Date
- XTNT 08-07-2025
- IKNA 08-07-2025
- Dividend Yield
- XTNT N/A
- IKNA N/A
- EPS Growth
- XTNT N/A
- IKNA N/A
- EPS
- XTNT N/A
- IKNA N/A
- Revenue
- XTNT $122,298,000.00
- IKNA N/A
- Revenue This Year
- XTNT $11.64
- IKNA N/A
- Revenue Next Year
- XTNT $7.59
- IKNA N/A
- P/E Ratio
- XTNT N/A
- IKNA N/A
- Revenue Growth
- XTNT 20.81
- IKNA N/A
- 52 Week Low
- XTNT $0.33
- IKNA $0.97
- 52 Week High
- XTNT $0.80
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- XTNT 44.76
- IKNA 43.13
- Support Level
- XTNT $0.56
- IKNA $1.33
- Resistance Level
- XTNT $0.67
- IKNA $1.47
- Average True Range (ATR)
- XTNT 0.05
- IKNA 0.06
- MACD
- XTNT -0.01
- IKNA -0.01
- Stochastic Oscillator
- XTNT 21.14
- IKNA 4.76
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.